# Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

> **NCT06468644** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** chemoradiotherapy （CRT）+sintilimab 1
- **DRUG:** CRT+sintilimab 2

## Key facts

- **NCT ID:** NCT06468644
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-17
- **Primary completion:** 2026-06
- **Final completion:** 2027-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06468644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06468644, "Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06468644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*